Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. Novartis. https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept. Accessed 14 Dec 2019.

  2. 2.

    Allergan and molecular partners announce acceptance of U.S. FDA biologics license application and validation of EMA marketing authorisation for abicipar pegol in patients with neovascular (Wet) age-related macular degeneration—molecular partners. https://www.molecularpartners.com/allergan-and-molecular-partners-announce-acceptance-of-u-s-fda-biologics-license-application-and-validation-of-ema-marketing-authorisation-for-abicipar-pegol-in-patients-with-neovascular-wet-age-re/. Accessed 30 Jul 2020.

  3. 3.

    Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019:S0161642018330185. https://doi.org/10.1016/j.ophtha.2019.04.017.

  4. 4.

    Kunimoto D, Yoon YH, Wykoff CC, Chang A, Khurana RN, Maturi RK, et al. Efficacy and safety of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2020:S0161642020303201. https://doi.org/10.1016/j.ophtha.2020.03.035.

  5. 5.

    Clinical Updates: Beovu Update for ASRS Members. https://www.asrs.org/clinical/clinical-updates/960/Beovu-Update-for-ASRS-Members. Accessed 27 Feb 2020.

  6. 6.

    Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, et al. Brolucizumab—early real-world experience: BREW study. Eye Published Online First: 24 July 2020. https://doi.org/10.1038/s41433-020-1111-x.

  7. 7.

    Safety of Beovu® (brolucizumab). https://www.brolucizumab.info/. Accessed 19 Jun 2020.

  8. 8.

    Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections—(MERLIN). https://clinicaltrials.gov/ct2/show/NCT03710564. Accessed 14 Dec 2019.

  9. 9.

    Jain A, Chea S, Matsumiya W, Sohail Halim M, Yaşar Ç, Kuang G, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18:100687. https://doi.org/10.1016/j.ajoc.2020.100687.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Haug SJ, Hien DL, Uludag G, Ngoc TTT, Lajevardi S, Sohail Halim M, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680. https://doi.org/10.1016/j.ajoc.2020.100680.

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Baumal CR, Spaide RF, Vajzovic L, Bailey Freund K, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology 2020;S0161642020303717. https://doi.org/10.1016/j.ophtha.2020.04.017.

  12. 12.

    Witkin AJ, Hahn P, Murray TG. Occlusive Retinal vasculitis following intravitreal brolucizumab: an ASRS research and safety in therapeutics (ReST) Committee Report. Retina Times;38. https://www.asrs.org/retina-times/details/3937/occlusive-retinal-vasculitis-following-intravitreal-brolucizumab-an-asrs-research-and-safety-in-ther. Accessed 19 Jun 2020.

  13. 13.

    Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn’t blind people, people blind people. Am J Ophthalmol. 2012;153:196–203.e1. https://doi.org/10.1016/j.ajo.2011.11.023.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    New Batches of Ranibizumab Biosimilar Safe, Effective. Medscape. http://www.medscape.com/viewarticle/867481. Accessed 19 Jun 2020.

  15. 15.

    Greenberg JP, Belin P, Butler J, Feiler D, Mueller C, Tye A, et al. Aflibercept-related sterile intraocular inflammation outcomes. Ophthalmol Retin. 2019;3:753–9. https://doi.org/10.1016/j.oret.2019.04.006.

    Article  Google Scholar 

  16. 16.

    Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol—Molecular Partners. https://www.molecularpartners.com/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol/. Accessed 25 Aug 2019.

  17. 17.

    Sharma A, Kumar N, Kuppermann BD, Loewenstein A, Bandello F. Brolucizumab: is extended VEGF suppression on the horizon? Eye. 2019. https://doi.org/10.1038/s41433-019-0582-0.

  18. 18.

    Novartis Pharmaceuticals Corporation. Beovu (brolucizumab-dll) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf. Revised October 7, 2019. Accessed June 2020.

  19. 19.

    Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, et al. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol. 2013;33:1192–203. https://doi.org/10.1007/s10875-013-9915-0.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Genentech, Inc. Lucentis (ranibizumab)[package insert]. U.S. Food and Drug Administration website https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105lbl.pdf. Revised October 2014. Accessed June 2020.

  21. 21.

    Patel NA, Berrocal AM, Murray TG, Villegas VM. Advanced Coats’ disease treated with intravitreal brolucizumab combined with laser photocoagulation. Am J Ophthalmol Case Rep. 2020;19:100815. https://doi.org/10.1016/j.ajoc.2020.100815.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ashish Sharma.

Ethics declarations

Conflict of interest

AS: Consultant: for Novartis, Allergan, Bayer and Intas. FB: Consultant: Allergan, Bayer, Boehringer- Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. BDK: Clinical research: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; Consultant: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. AL reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsights labs, other from Beyeonics, other from Bayer Health Care. NK: None. NP: None. SS: None.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Kumar, N., Parachuri, N. et al. Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. Eye (2020). https://doi.org/10.1038/s41433-020-01227-w

Download citation

Search